lass of 'relevant securities' of Warner Chilcott or Actavis, all 'dealings' in any 'relevant securities' of Warner Chilcott or Actavis (including by means of an option in respect of, or a derivative referenced to, any such 'relevant securities') must be publicly disclosed by not later than 3:30 p.m. (Dublin time) on the business day following the date of the relevant transaction. This requirement will continue until the date on which the Scheme becomes effective or on which the 'offer period' otherwise ends. If two or more persons co-operate on the basis of any agreement, either express or tacit, either oral or written, to acquire an 'interest' in 'relevant securities' of Warner Chilcott or Actavis, they will be deemed to be a single person for the purpose of Rule 8.3 of the Irish Takeover Rules.
Under the provisions of Rule 8.1 of the Irish Takeover Rules, all 'dealings' in 'relevant securities' of Warner Chilcott by Actavis or 'relevant securities' of Actavis by Warner Chilcott, or by any of their respective 'associates' must also be disclosed by no later than 12 noon (Dublin time) on the 'business' day following the date of the relevant transaction.
A disclosure table, giving details of the companies in whose 'relevant securities' 'dealings' should be disclosed, can be found on the Irish Takeover Panel's website at www.irishtakeoverpanel.ie.
'Interests in securities' arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having an 'interest' by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities.
Terms in quotation marks are defined in the Irish Takeover Rules, which can also be found on the Irish Takeover Panel's website. If you are in any doubt as to whether or not you are required to dPage: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Related medicine technology :1
. Watson to Acquire Actavis Group for EUR4.25 Billion2
. Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets)3
. Actavis Launches Generic Equivalent of Adalat® CC 90mg (Nifedipine Extended-Release Tablets, USP)4
. Watson and Actavis Receive FTC Second Request5
. Watson Announces New Name -- Actavis -- for Global Operations6
. Watson Pharmaceuticals, Inc. is Now Actavis, Inc.7
. Actavis, Inc. to Host Fourth Quarter 2012 Earnings Conference Call and Webcast8
. Actavis, Inc. to Present at the RBC Capital Markets Healthcare Conference9
. Actavis Full Year 2012 Net Revenue Increases 29% to $5.91 Billion10
. Actavis, Inc. to Present at the Cowen & Company 33rd Annual Health Care Conference11
. Actavis, Inc. to Present at the Barclays 2013 Global Healthcare Conference